Bayer and Aventis Sign Letter of Intent on Joint Venture of Blood Plasma Business
Substantial boost planned for the Health Care business:
21-Feb-2002 -
Leverkusen - Bayer AG and Aventis have signed a non-binding letter of intent to establish a joint venture for biological products. The companies plan to combine Bayer's Biological Products Business Group with the Aventis subsidiary Aventis Behring, with Bayer owning a substantial majority ...
Aventis
Bayer
genetic engineering
+3